Kura Oncology

Ziftomenib (KOMZIFTI) is an oral small-molecule therapeutic developed by Kura Oncology for acute myeloid leukemia (AML). The drug received FDA approval under application number NDA220305, marking a significant regulatory milestone for the sponsor. Currently, ziftomenib is advancing through phase 3 clinical development, with the most recent milestone recorded on 14 April 2026. The program is identified by internal code KO-MEN-008 and operates without disclosed partnership arrangements.

As an oral small-molecule agent, ziftomenib represents Kura Oncology's strategic focus on hematologic malignancies. The drug's mechanism of action and specific molecular target remain undisclosed in available regulatory documentation. The approval of the branded formulation KOMZIFTI establishes commercial infrastructure for the program, though peak sales projections and detailed clinical efficacy data are not yet disclosed.

Ziftomenib competes within a crowded AML therapeutic landscape that includes approved agents such as venetoclax (AbbVie) and olutasidenib (Rigel Pharmaceuticals), as well as multiple phase 3 programs from international sponsors. The program's phase 3 status indicates ongoing clinical evaluation, with regulatory catalysts expected as trial data mature. The oral route of administration provides potential convenience advantages over intravenous alternatives in the AML treatment armamentarium.

Acute myeloid leukemia remains a serious hematologic malignancy with limited treatment options, particularly for relapsed/refractory disease and elderly patients ineligible for intensive chemotherapy. The AML market has expanded significantly with the introduction of targeted therapies and venetoclax-based combinations, yet substantial unmet medical need persists. Ziftomenib's oral formulation addresses patient convenience and quality-of-life considerations compared to intravenous regimens.

Competitive positioning is critical in this space. Approved competitors include venetoclax (AbbVie), a BCL-2 inhibitor widely used in combination regimens, and olutasidenib (Rigel Pharmaceuticals), a menin inhibitor. Multiple phase 3 programs are advancing, including revumenib (Syndax Pharmaceuticals) and various venetoclax combinations, indicating sustained industry investment in AML therapeutics. The specific mechanism of action for ziftomenib is not yet disclosed, limiting detailed competitive differentiation analysis.

Commercial significance is substantial given AML's high treatment burden and the emergence of premium-priced targeted therapies. However, market penetration depends on efficacy, safety, and tolerability data from phase 3 trials. The FDA approval of KOMZIFTI establishes regulatory validation, though clinical differentiation versus existing and emerging competitors remains to be demonstrated through published trial results. Patient population size, reimbursement landscape, and real-world adoption patterns will ultimately determine commercial success.

Drug Class: Small-molecule oncology therapeutic

Modality: Small molecule

Route of Administration: Oral

Brand Name: KOMZIFTI

International Nonproprietary Name (INN): Ziftomenib

Mechanism of Action: Not yet disclosed

Molecular Target: Not yet disclosed

Therapeutic Class: Not yet disclosed

Related Therapies in AML: Venetoclax (BCL-2 inhibitor), olutasidenib (menin inhibitor), gilteritinib (FLT3 inhibitor), revumenib (menin inhibitor), conventional chemotherapy regimens including cytarabine and daunorubicin

Patent Status: Not yet disclosed

First Approval: FDA approval granted; application number NDA220305

United States (FDA): Ziftomenib (KOMZIFTI) has received FDA approval under New Drug Application (NDA) number NDA220305. Approval date is not disclosed in available regulatory documentation. The drug is marketed under the brand name KOMZIFTI with sponsor attribution to Kura Oncology.

European Medicines Agency (EMA): Regulatory status not yet disclosed.

Pharmaceuticals and Medical Devices Agency (PMDA, Japan): Regulatory status not yet disclosed.

National Medical Products Administration (NMPA, China): Regulatory status not yet disclosed.

Clinical Trial Registration: NCT06001788 is registered; trial details including primary endpoints, enrollment status, and results are not yet disclosed.

Strategic Implications for Kura Oncology: FDA approval of KOMZIFTI validates Kura's oncology pipeline and establishes commercial infrastructure for AML market entry. The absence of disclosed partnership arrangements suggests Kura is pursuing independent commercialization, requiring substantial sales and marketing investment. Phase 3 advancement indicates confidence in clinical efficacy, though peak sales projections remain undisclosed.

Competitive Implications: Ziftomenib enters a market increasingly dominated by oral small molecules and menin inhibitors. If ziftomenib's mechanism is menin inhibition (consistent with competitive positioning), it would compete directly with olutasidenib and revumenib. Differentiation will require superior efficacy in specific patient populations, improved safety/tolerability profiles, or synergistic combination potential. The crowded phase 3 pipeline suggests market saturation risk if clinical advantages are not clearly demonstrated.

Future Catalysts: Phase 3 trial readouts represent the primary near-term catalyst. Disclosure of mechanism of action and molecular target would enable detailed competitive positioning. Label expansion opportunities (e.g., newly diagnosed AML, specific molecular subtypes) could broaden market applicability. Real-world evidence and comparative effectiveness data will influence adoption post-approval.

Expected Milestones: Phase 3 trial completion and regulatory submissions are anticipated, though specific timelines are not disclosed. Potential label expansions or combination therapy approvals may follow initial indication approval. International regulatory submissions to EMA, PMDA, and NMPA would expand commercial opportunity, though no timelines are disclosed.